论文部分内容阅读
高脂血症是缺血性心脏病发病机理中主要因素之一,降低血脂成为预防和治疗缺血性心脏病的主要组成部分。血脂康是新一代纯天然中药制剂的调脂药,因含羟甲基戊二酰辅酶A(HMG—CoA)还原酶抑制剂洛伐他丁及多种不饱和脂肪酸和人体必需氨基酸而可能具有调节血脂代谢作用。为了证实其调脂作用,我们于1997年8月至1998年5月对46例老年高脂血症病人应用血脂康进行了临床疗效观察。现总结如下:
Hyperlipidemia is one of the main factors in the pathogenesis of ischemic heart disease. Reducing blood lipids is a major component of prevention and treatment of ischemic heart disease. Xuezhikang is a new generation of natural herbal preparations of lipid-lowering drugs, due to methylhydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor lovastatin and a variety of unsaturated fatty acids and essential amino acids in the human body may have Regulate blood lipid metabolism. In order to confirm its lipid-lowering effect, we observed the clinical efficacy of Xuezhikang in 46 elderly patients with hyperlipemia from August 1997 to May 1998. Now summarized as follows: